高收入国家老年人侵袭性肺炎球菌病的血清型分布及儿童与成人疫苗接种政策的影响
研究收集33个高收入国家老年人(多数国家≥65岁)的血清型特异性侵袭性肺炎球菌病(IPD)数据,共52,905例有血清型鉴定的IPD病例。PCV13血清型占33.7%,PCV15和PCV20可额外覆盖10.4%和32.9%的PCV13以外血清型IPD。结论认为接种高价肺炎球菌结合疫苗(尤其PCV20)可大幅减少剩余IPD负担。
要点
- PCV13血清型占老年人IPD的33.7%,最常见为血清型3(14.9%)和19A(7.0%)。
- PCV15和PCV20可额外覆盖PCV13以外10.4%和32.9%的IPD。
- PPSV23政策与PPSV23血清型IPD百分比降低不相关。
核心结论
- 为老年人接种高价肺炎球菌结合疫苗(尤其PCV20)可大幅减少高收入国家剩余的IPD负担,无论当前儿童国家免疫规划中PCV使用情况及成人PPSV23政策如何。
研究设计与样本
- 研究收集来自33个高收入国家国家或区域监测系统或医院网络的老年人(多数国家≥65岁)血清型特异性IPD数据。
- 数据来源包括政府官方网站、在线数据库、监测系统报告、已发表文献及与国内研究者的个人交流。
- 计算IPD血清型的平均百分比。
主要发现
- 在52,905例有血清型鉴定的IPD病例中,PCV13血清型占33.7%(儿童国家免疫规划使用PCV10和PCV13的国家分别为55.8%和30.6%),最常见为血清型3(14.9%)和19A(7.0%)。
- PCV15和PCV20可额外覆盖PCV13以外10.4%和32.9%的老年人IPD(PCV10国家:7.7%和23.3%;PCV13国家:10.6%和34.6%)。
- 这些额外血清型中最常见的是8(9.9%)、22F(7.9%)、12F(4.6%)和11A(3.3%)。
- 针对老年人的PPSV23政策与PPSV23血清型所致IPD百分比降低不相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neither indirect protection through use of 13-valent and 10-valent pneumococcal conjugate vaccines (PCV13 and PCV10) in pediatric National Immunization Programs (NIPs) nor direct vaccination with the 23-valent polysaccharide vaccine have eliminated vaccine serotype invasive pneumococcal disease (IPD) in older adults. Vaccinating older adults with higher-valency PCV15 and PCV20 could address remaining IPD due to pediatric PCV serotypes plus additional IPD due to serotypes included in these vaccines. METHODS: We collected serotype-specific IPD data in older adults (≥65 years in most countries), from national or regional surveillance systems or hospital networks of 33 high-income countries. Data were from official government websites, online databases, surveillance system reports, published literature, and personal communication with in-country investigators. Average percentages of IPD serotypes were calculated. RESULTS: Among 52,905 cases of IPD with a serotype identified, PCV13 serotypes accounted for 33.7% of IPD (55.8% and 30.6% for countries with PCV10 and PCV13 in the pediatric NIP), most commonly serotypes 3 (14.9%) and 19A (7.0%). PCV15 and PCV20 would cover an additional 10.4% and 32.9% of older adult IPD beyond PCV13 serotypes (PCV10 countries: 7.7% and 23.3%; PCV13 countries: 10.6% and 34.6%). The most common of these additional serotypes were 8 (9.9%), 22F (7.9%), 12F (4.6%), and 11A (3.3%). PPSV23 policies for older adults were not correlated with lower IPD percentages due to PPSV23 serotypes. CONCLUSIONS: Vaccinating older adults with higher-valency PCVs, especially PCV20, could substantially reduce the remaining IPD burden in high-income countries, regardless of current PCV use in pediatric NIPs and adult PPSV23 policies.
引用
- Grant LR, Slack MPE, Theilacker C, et al. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine. 2023. PMID: 37544825. doi:10.1016/j.vaccine.2023.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。